Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Edwards Lifesciences Corporation    EW

EDWARDS LIFESCIENCES CORPORATION (EW)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Edwards Lifesciences Corp : Edwards Lifesciences' Chairman and CEO to Exercise Stock Options Under 10b5-1 Stock Trading Plan

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/01/2013 | 04:37pm CEST

IRVINE, CA, March 01, 2013 -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that its chairman and chief executive officer, Michael A. Mussallem, has adopted a pre-arranged stock trading plan under Rule 10b5-1 of the Securities and Exchange Act of 1934. In May 2013, the plan will begin exercising stock options, the vast majority of which are scheduled to expire in 2014.

The plan anticipates the exercise and sale of 29,500 shares per month at market prices between May 2013 and April 2014. Rule 10b5-1 allows corporate executives to adopt stock trading plans to buy or sell shares of company stock when they are not in possession of material, non-public information. Mussallem plans to enter into similar types of trading plans each year as stock options near their expiration dates in order to spread sales evenly over an extended period of time.

Under the company's stock ownership guidelines, Mussallem is required to own shares of company stock with an aggregate market value equal to six times his base salary. At the conclusion of the plans, Mussallem will still hold shares well in excess of the number required to meet these guidelines. Transactions under these plans will be disclosed publicly through Form 144 and Form 4 filings with the U.S. Securities and Exchange Commission. The Form 4 filings will also be posted on Edwards' investor relations Web site at ir.edwards.com.

About Edwards Lifesciences
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives. Additional company information can be found at edwards.com.

Edwards, Edwards Lifesciences and the stylized E logo are trademarks of Edwards Lifesciences Corporation.

# # #


distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EDWARDS LIFESCIENCES CORPO
08:37pEDWARDS LIFESCIENCES : Federal Contracts Awarded by Federal Agencies in Iowa (Ma..
AQ
05/25EDWARDS LIFESCIENCES : Patent Issued for Methods for Ensuring Safe and Rapid Dep..
AQ
05/25EDWARDS LIFESCIENCES : Patent Application Titled "Heart Valve Delivery System wi..
AQ
05/25EDWARDS LIFESCIENCES : Patent Issued for Detecting a Vasoactive Agent in the Blo..
AQ
05/25EDWARDS LIFESCIENCES : Researchers Submit Patent Application, "Apparatus for the..
AQ
05/25EDWARDS LIFESCIENCES : Patent Issued for Cardiac Implant with Integrated Suture ..
AQ
05/24ESOPHAGEAL STENTS MARKET STATUS AND : The global Esophageal Stents market Resea..
AQ
05/24EDWARDS LIFESCIENCES : To Present At The Bernstein 34th Annual Strategic Decisio..
PR
05/23EDWARDS LIFESCIENCES : Federal Contracts Awarded by Federal Agencies in Minnesot..
AQ
05/22EDWARDS LIFESCIENCES : Real-World Evidence Confirms Clinical Trial Outcomes For ..
PU
More news
News from SeekingAlpha
05/12EDWARDS LIFESCIENCES : Treating The #1 Killer In America 
05/01Edwards launches $400M accelerated share buyback program 
04/25PREMARKET LOSERS AS OF 9 : 05 am (4/25/2018) 
04/25Premarket analyst action - healthcare 
04/25Sell-siders weigh in on Edwards Lifesciences after Q1 report; shares down 8% 
Financials ($)
Sales 2018 3 846 M
EBIT 2018 1 165 M
Net income 2018 952 M
Finance 2018 291 M
Yield 2018 -
P/E ratio 2018 30,05
P/E ratio 2019 26,81
EV / Sales 2018 7,38x
EV / Sales 2019 6,60x
Capitalization 28 655 M
Chart EDWARDS LIFESCIENCES CORPO
Duration : Period :
Edwards Lifesciences Corpo Technical Analysis Chart | EW | US28176E1082 | 4-Traders
Technical analysis trends EDWARDS LIFESCIENCES CORPO
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 146 $
Spread / Average Target 7,7%
EPS Revisions
Managers
NameTitle
Michael A. Mussallem Chairman & Chief Executive Officer
Scott B. Ullem Chief Financial Officer & Vice President
Stanton J. Rowe Chief Scientific Officer & VP-Advanced Technology
John P. McGrath Vice President-Quality, Regulatory & Clinical
William J. Link Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
EDWARDS LIFESCIENCES CORPORATION23.38%28 655
THERMO FISHER SCIENTIFIC12.52%85 956
DANAHER CORPORATION10.15%71 345
INTUITIVE SURGICAL25.44%51 726
BOSTON SCIENTIFIC CORPORATION23.64%41 822
ROYAL PHILIPS13.78%39 823